LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Autor:	S.M. Lee, C. Schulz, K. Prabhash, B. Han, A. Szczesna, D.L. Cortinovis, A. Rittmeyer, D. Vicente Baz, R. Califano, L. Tuan Anh, G. Liu, F. Cappuzzo, J.G. Reyes Contreras, M. Reck, Y. Hu, S. Morris, E.K. Hoeglander, M. Connors, H.K.M. Vollan, S. Peters
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1418-S1419
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f84eef72515c52a287ab74df236e5557 https://doi.org/10.1016/j.annonc.2022.08.052 Zobrazit plný text záznamu